NASDAQ$VTGN
Vistagen Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for its fiscal year 2022 first quarter and provided a corporate update.
VistaGen Therapeutics reported financial results for its fiscal year 2022 first quarter ended June 30, 2021. The company recognized $0.4 million in sublicense revenue. Research and development expense increased by $3.9 million, and general and administrative expense increased to approximately $2.5 million. Net loss for the quarter was approximately $7.7 million. The Company had cash and cash equivalents of approximately $97.8 million at June 30, 2021.
- Initiated PALISADE Phase 3 Program with PALISADE-1.
- Expects to initiate PALISADE-2 in the second half of calendar 2021.
- Received notice from the FDA allowing commencement of its exploratory Phase 2A clinical study of PH94B in adults experiencing AjDA.
- Preparing to initiate a Phase 1B clinical study to evaluate AV-101 in combination with probenecid during the second half of calendar 2021.
Headline financials
Revenue & EPS history
Vistagen · Revenue · Quarterly
$354K
Revenue by segment
Vistagen · $400K total across 1 segment · Q1 2022
- Sublicense and other revenue$400K—100.0%
Forward guidance
VistaGen is focused on advancing its clinical-stage programs through multiple development and regulatory milestones. They are preparing for exploratory Phase 2A clinical studies of PH94B in adults experiencing other anxiety disorders, including postpartum anxiety, post-traumatic stress disorder and pre-procedural anxiety. They are also preparing to initiate a Phase 2B multi-center study to evaluate the efficacy, safety and tolerability of PH10 as a potential rapid-onset treatment for MDD in mid-2022.
Tailwinds
- Initiation of PALISADE-2 expected in the second half of calendar 2021.
- Exploratory Phase 2A clinical study of PH94B in adults experiencing AjDA expected to start by the end of 2021.
- Preparation for exploratory Phase 2A clinical studies of PH94B in adults experiencing other anxiety disorders.
- Preparation to initiate a Phase 2B multi-center study to evaluate PH10 as a potential rapid-onset treatment for MDD in mid-2022.
- Phase 1B clinical study to evaluate AV-101 in combination with probenecid during the second half of calendar 2021.
Headwinds
- Delays in launching and/or conducting planned clinical trials due to the impact of the ongoing COVID-19 pandemic.
- Fluctuating costs of materials and other resources required to conduct planned clinical and non-clinical trials.
- Impact of general economic, industry or political conditions in the United States or internationally.
- Adverse healthcare reforms and changes of laws and regulations.
- Manufacturing and marketing risks, including unavailability of or delays in delivery of raw materials.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+2.5%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+1.1%
Avg return
30 days after
39%
23 / 59 earnings
Positive
+94.1%
Q4 2012
Best reaction
-24.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +19.2% | +17.1% | — | |
| Q3 2026 | -3.5% | -7.0% | +7.0% | |
| Q2 2026 | +0.0% | +18.4% | +11.8% | |
| Q1 2026 | +8.1% | +7.3% | +30.0% | |
| Q4 2025 | +7.0% | +5.7% | -3.9% | |
| Q3 2025 | +4.2% | +0.0% | -5.3% | |
| Q2 2025 | +1.3% | -5.5% | -16.1% | |
| Q1 2025 | -2.7% | -2.7% | -5.3% | |
| Q4 2024 | +0.3% | -4.3% | +6.3% | |
| Q3 2024 | +4.7% | -1.0% | -23.9% | |
| Q2 2024 | -16.6% | +3.2% | +51.0% | |
| Q1 2024 | -8.8% | -10.8% | -4.3% | |
| Q4 2023 | +6.5% | +19.5% | +7.1% | |
| Q3 2023 | -24.0% | -28.0% | -44.0% | |
| Q2 2023 | +45.5% | +45.5% | +9.1% | |
| Q1 2023 | -5.9% | -5.9% | +23.5% | |
| Q4 2022 | -3.9% | -10.8% | -85.3% | |
| Q3 2022 | -7.4% | -1.2% | -26.5% | |
| Q2 2022 | +0.4% | -7.7% | -21.0% | |
| Q1 2022 | +2.2% | +0.0% | +11.4% | |
| Q4 2021 | +10.9% | +19.4% | -5.6% | |
| Q3 2021 | -5.0% | -1.0% | +16.9% | |
| Q2 2021 | +2.9% | +5.9% | +8.8% | |
| Q1 2021 | -7.3% | -14.6% | -25.6% | |
| Q4 2020 | +1.9% | +1.9% | +76.9% | |
| Q3 2020 | -12.2% | -10.8% | -45.9% | |
| Q2 2020 | +0.9% | +0.0% | -58.9% | |
| Q1 2020 | -12.7% | -7.3% | +100.0% | |
| Q4 2019 | -5.3% | -2.7% | -30.7% | |
| Q3 2019 | -2.9% | -16.1% | -26.4% | |
| Q2 2019 | -3.3% | -0.9% | -19.3% | |
| Q1 2019 | -3.1% | +2.3% | +8.6% | |
| Q4 2018 | +1.5% | +3.0% | -2.3% | |
| Q3 2018 | +3.4% | +8.6% | +9.5% | |
| Q2 2018 | -1.3% | -3.7% | +125.0% | |
| Q1 2018 | +0.0% | +5.2% | -6.4% | |
| Q4 2017 | +2.2% | -3.3% | +11.5% | |
| Q3 2017 | -10.2% | -19.3% | -28.8% | |
| Q2 2017 | +2.4% | -1.1% | -6.1% | |
| Q1 2017 | +6.3% | +7.8% | +28.5% | |
| Q4 2016 | -9.9% | -4.2% | -8.8% | |
| Q3 2016 | +0.0% | — | — | |
| Q2 2016 | +0.0% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | -1.5% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | -8.6% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +94.1% | — | — | |
| Q4 2012 | +94.1% | — | — | |
| Q3 2012 | +1.8% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q1 2010 | — | — | — | |
| Q4 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro